![]() |
市場調查報告書
商品編碼
1372014
2030 年電化學生物感測器市場預測:按類型、用途和地區分類的全球分析Electrochemical Biosensors Market Forecasts to 2030 - Global Analysis By Type (Diagnosis and Monitoring), By Application (Healthcare Diagnostics, Point Of Care Testing, Research Laboratories and Other Applications) and By Geography |
根據 Stratistics MRC 的數據,2023 年全球電化學生物感測器市場規模為 172.7 億美元,預計在預測期內年複合成長率為 8.65%,到 2030 年將達到 308.7 億美元。
電化學生物感測器是將電化學感測器與生物辨識成分(例如酵素、抗體或 DNA)結合的分析工具,用於鑒定和檢測特定分析物或生物分子。它的工作原理是基於識別元件和目標分析物相互作用引起的電化學反應。這些生物感測器經常用於選擇性和靈敏地檢測各種物質,包括生物標記、病原體和環境污染物。
根據國際糖尿病聯盟的數據,預計到 2035 年將有超過 5.9 億人患有糖尿病,這意味著市場在整個預測期內將快速擴張。
對現場檢測的需求不斷成長是電化學生物感測器市場的主要促進因素。現場護理測試提供快速、便捷的診斷解決方案,使醫療保健專業人員能夠在患者床邊或遠端做出即時決策。電化學生物感測器由於其高靈敏度和快速結果而非常適合這些用途。促進疾病的早期發現、持續監測和及時干涉,特別是在緊急情況和慢性病管理方面。人們越來越重視可及且負擔得起的醫療保健,特別是在資源匱乏的地區,這正在推動電化學生物感測器在現場檢測中的採用,並推動市場擴張。
開發先進的生物感測器技術成本高昂,影響了這些設備的承受能力。高製造成本可能會阻礙廣泛普及,特別是在資源有限的醫療保健環境和新興市場。此外,對精確品管的需求增加了製造成本,這進一步限制了市場成長。
醫療保健領域的技術進步為電化學生物感測器市場創造了巨大的機會。隨著小型化、無線連接和資料分析的進步,生物感測器變得更加複雜且更容易使用。這些進步實現了即時監控、遠端醫療應用以及將生物感測器整合到穿戴式設備中,以增強患者照護和疾病管理。此外,生物感測器與人工智慧和物聯網等新興技術的整合將進一步擴展其能力,並為創新診斷和監測解決方案提供機會。
有關醫療保健設備使用的嚴格法規對電化學生物感測器市場構成了重大威脅。醫用生物感測器的開發和商業化需要滿足複雜的法規要求網路,包括衛生當局的核准。遵守這些嚴格的法規非常耗時、成本高昂且具有挑戰性,並且可能會延遲我們產品的推出或阻止我們進入市場。此外,嚴格的要求也可能抑制中小企業的市場准入。
COVID-19 的爆發對電化學生物感測器市場產生了積極影響。儘管對快速準確檢測病毒的生物感測器的需求有所增加,但供應鏈和臨床業務的中斷帶來了挑戰。對即時檢測解決方案的需求以及用於檢測 SARS-CoV-2 抗體的生物感測器的開發推動了創新。然而,研發活動的延遲和供應鏈的限制影響了更廣泛的市場。隨著疫情消退,市場預計將復甦,重點關注感染疾病診斷以外的多種用途。
由於對快速、準確和方便用戶使用的診斷解決方案的需求不斷成長,診斷領域預計將主導市場。診斷在生物標記、病原體和疾病相關分子的檢測中提供高靈敏度和特異性。生物感測器具有從臨床診斷到環境和食品安全的廣泛應用,是早期疾病檢測、監測和研究的寶貴工具。它為診斷和現場護理測試位置提供即時資料的能力正在推動細分市場的擴張。
由於對快速和分散診斷解決方案的需求不斷成長,預測在預測期內,現場護理測試領域將推動市場發展。電化學生物感測器由於其攜帶性、快速結果和易於使用而適合 POC 應用。它使醫療保健專業人員能夠在患者身邊及時做出決策,為更好的疾病管理和早期檢測提供即時見解。此外,POC 測試在資源有限的環境、偏遠地區和緊急情況下至關重要。隨著全球轉向可及且負擔得起的醫療保健,電化學生物感測器在 POC 環境中的採用預計將激增,從而推動市場成長。
在預測期內,由於醫療保健支出的增加和即時檢測技術的採用,北美預計將佔據最大的市場。主要生物技術和製藥公司的存在以及對醫療保健的大量投資正在推動該地區的技術進步和創新生物感測器應用。此外,北美完善的醫療保健系統和不斷增加的老年人口正在促進市場成長,使其成為全球電化學生物感測器市場的主導者。
由於醫療保健意識的提高、慢性病患病的增加以及對疾病早期檢測的興趣日益濃厚,亞太地區的電化學生物感測器市場正在顯著成長。在這個人口稠密且多元化的地區,對診斷工具和醫療設備的需求正在上升。此外,政府加強醫療基礎設施的配合措施和生物感測器技術的技術進步正在進一步推動市場擴張。
According to Stratistics MRC, the Global Electrochemical Biosensors Market is accounted for $17.27 billion in 2023 and is expected to reach $30.87 billion by 2030 growing at a CAGR of 8.65% during the forecast period. Electrochemical biosensors are analytical tools that combine an electrochemical transducer with a biological recognition component (such as enzymes, antibodies, or DNA) to identify and measure particular analytes or biomolecules. Based on the electrochemical reaction caused by the interaction of the recognition element and the target analyte, they function. These biosensors are frequently used to measure a variety of substances, including biomarkers, pathogens, environmental pollutants, and more, in a selective and sensitive manner.
According to the International Diabetic Federation more than 590 million people are expected to develop diabetes by 2035, implying that the market would increase rapidly throughout the projected period.
The increased demand for point-of-care testing serves as a key driver in the electrochemical biosensor market. Point-of-care testing offers rapid and convenient diagnostic solutions, enabling healthcare professionals to make real-time decisions at the patient's bedside or in remote settings. Electrochemical biosensors, with their high sensitivity and quick results, are well-suited for these applications. They facilitate early disease detection, continuous monitoring, and timely interventions, particularly in emergency situations and for chronic disease management. The growing emphasis on accessible and affordable healthcare, especially in resource-limited areas, is propelling the adoption of electrochemical biosensors in point-of-care testing, driving market expansion.
The development of advanced biosensor technologies can be expensive, impacting the affordability of these devices. High production costs can hinder their widespread adoption, especially in resource-limited healthcare settings and emerging markets. Additionally, the need for precise quality control adds to production costs, which further restrains market growth.
Technological advancements in the healthcare sector present a significant opportunity in the electrochemical biosensor market. With the ongoing development of miniaturization, wireless connectivity, and data analytics, biosensors are becoming more sophisticated and user-friendly. These advancements enable real-time monitoring, telehealth applications, and the integration of biosensors into wearable devices, thus enhancing patient care and disease management. Moreover, the convergence of biosensors with emerging technologies like artificial intelligence and the Internet of Things further expands their capabilities, offering opportunities for innovative diagnostic and monitoring solutions.
Strict regulations for the use of healthcare equipment pose a notable threat to the electrochemical biosensor market. The development and commercialization of biosensors for medical purposes involve navigating a complex web of regulatory requirements, including approvals from health authorities. Compliance with these stringent regulations is time-consuming, costly, and often challenging, potentially delaying product launches and hindering market entry. Moreover, stringent requirements may also discourage smaller players from entering the market.
The COVID-19 pandemic has had a positive impact on the electrochemical biosensor market. While there was increased demand for biosensors for rapid and accurate testing of the virus, disruptions in supply chains and clinical operations created challenges. The need for point-of-care testing solutions and the development of biosensors for detecting SARS-CoV-2 antibodies drove innovation. However, the broader market was influenced by delays in research and development activities and supply chain constraints. As the pandemic recedes, the market is expected to rebound with a focus on diverse applications beyond infectious disease diagnostics.
The diagnosis segment is predicted to dominate the market due to the growing demand for rapid, accurate, and user-friendly diagnostic solutions. Diagnosis offers high sensitivity and specificity in detecting biomarkers, pathogens, and disease-related molecules. With applications ranging from clinical diagnostics to environmental and food safety, biosensors are invaluable tools for early disease detection, monitoring, and research. Their ability to provide real-time data and point-of-care testing positions for diagnosis is propelling segment expansion.
The point of care testing segment is poised to drive the market during the forecast period, owing to the increasing demand for rapid and decentralized diagnostic solutions. Electrochemical biosensors, with their portability, quick results, and ease of use, are well-suited for POC applications. They empower healthcare professionals to make timely decisions at the patient's side, offering real-time insights for better disease management and early detection. Moreover, POC testing is crucial in resource-limited settings, remote areas, and emergency situations. With a global shift towards accessible and affordable healthcare, the adoption of electrochemical biosensors in POC settings is expected to surge, propelling market growth.
During the forecast period, North America is anticipated to account for the largest market owing to regions rising healthcare expenditure and the adoption of point-of-care testing technologies. The presence of major biotechnology and pharmaceutical companies, along with significant investments in healthcare, promotes technological advancements and innovative biosensor applications in the region. Moreover, North America's well-established healthcare system and a growing geriatric population contribute to the market's growth, making it a prominent player in the global electrochemical biosensors market.
The electrochemical biosensors market in the Asia Pacific is witnessing substantial growth due to rising healthcare awareness, increasing prevalence of chronic diseases, and a growing focus on early disease detection. With a large and diverse population, the region's demand for diagnostic tools and medical devices is on the rise. Additionally, government initiatives to enhance healthcare infrastructure and technological advancements in biosensor technologies are further driving the market's expansion.
Some of the key players in Electrochemical Biosensors market include: Abbott Laboratories, Bayer AG, Bio-Rad Laboratories, Biosensors International Group Ltd., Conductive Technologies Inc., I-SENS, Inc, Medtronics, Philips Healthcare, Roche Holding AG, Siemens Healthineers, Sysmex Corporation and Thermo Fisher Scientific.
In February 2023, FREDsense Technologies Corp., the leader in field-ready water testing kits that detect chemicals in drinking and wastewater, announced that their platform can detect and measure PFAS in just hours, compared to traditional methods.
In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes. The transaction expands Abbott's presence in diabetes care, building on its world-leading FreeStyle Libre® portfolio of continuous glucose monitoring technology and furthering the company's efforts to develop connected solutions for making diabetes management even more personal and precise.